The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Estrogen Replacement Therapy and Ovarian Cancer Mortality in a Large Prospective Study of US Women
Abstract
CONTEXT: Postmenopausal estrogen use is associated with increased risk of endometrial and breast cancer, 2 hormone-related cancers. The effect of postmenopausal estrogen use on ovarian cancer is not established. OBJECTIVES: To examine the association between postmenopausal estrogen use and ovarian cancer mortality and to determine whether the association differs according to duration and recency of use. DESIGN AND SETTING: The American Cancer Society's Cancer Prevention Study II, a prospective US cohort study with mortality follow-up from 1982 to 1996. PARTICIPANTS: A total of 211 581 postmenopausal women who completed a baseline questionnaire in 1982 and had no history of cancer, hysterectomy, or ovarian surgery at enrollment. MAIN OUTCOME MEASURE: Ovarian cancer mortality, compared among never users, users at baseline, and former users as well as by total years of use of estrogen replacement therapy (ERT). RESULTS: A total of 944 ovarian cancer deaths were recorded in 14 years of follow-up. Women who were using ERT at baseline had higher death rates from ovarian cancer than never users (rate ratio [RR], 1.51; 95% confidence interval [CI], 1.16-1.96). Risk was slightly but not significantly increased among former estrogen users (RR, 1.16; 95% CI, 0.99-1.37). Duration of use was associated with increased risk in both baseline and former users. Baseline users with 10 or more years of use had an RR of 2.20 (95% CI, 1.53-3.17), while former users with 10 or more years of use had an RR of 1.59 (95% CI, 1.13-2.25). Annual age-adjusted ovarian cancer death rates per 100 000 women were 64.4 for baseline users with 10 or more years of use, 38.3 for former users with 10 or more years of use, and 26.4 for never users. Among former users with 10 or more years of use, risk decreased with time since last use reported at study entry (RR for last use <15 years ago, 2.05; 95% CI, 1.29-3.25; RR for last use >/=15 years ago, 1.31; 95% CI, 0.79-2.17). CONCLUSIONS: In this population, postmenopausal estrogen use for 10 or more years was associated with increased risk of ovarian cancer mortality that persisted up to 29 years after cessation of use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SEER Cancer Statistics Review, 1975-2003
Ries, L. A. G., Harkins, D., Krapcho, M. F., Mariotto, A. B., Miller, B., Feuer, E. J., Clegg, L. X., Eisner, M. P., Horner, M., Howlader, N., et al. (2006) · Digital Archive @ GSU · Cited by 11,775
The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.
Colditz, G. A., Hankinson, S. E., Hunter, D. J., Willett, W. C., Manson, J. E., Stampfer, M. J., Hennekens, C., Rosner, B., & Speizer, F. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506153322401 · Cited by 1,487 · cited 1×
“Endometrial cancer incidence increases rapidly with use of unopposed estrogen(1,2); breast cancer incidence, however, increases only after long duration estrogen use.(3) Although there is evidence that pituitary and/or sex hormones play an important etiologic role in ovarian cancer,(4-6) epidemiologic studies of the a…”
BackgroundIncreased Risk of Endometrial Carcinoma among Users of Conjugated Estrogens
Ziel, H. K., & Finkle, W. D. (1975) · New England Journal of Medicine · doi:10.1056/nejm197512042932303 · Cited by 1,008
Whittmore, A. S., Harris, R., & Itnyre, J. (1992) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116427 · Cited by 1,000
Association of Exogenous Estrogen and Endometrial Carcinoma
Smith, D. C., Prentice, R., Thompson, D. J., & Herrmann, W. L. (1975) · New England Journal of Medicine · doi:10.1056/nejm197512042932302 · Cited by 960
Risch, H. A. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.23.1774 · Cited by 771
Determinants of Ovarian Cancer Risk. II. Inferences Regarding Pathogenesis 2
(1983) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/71.4.717 · Cited by 535
Hormone replacement therapy: Fortnightly review
Barrett-Connor, E. (1998) · BMJ · doi:10.1136/bmj.317.7156.457 · Cited by 403
Risk factors for ovarian cancer: a case-control study
Booth, M., Beral, V, & Smith, P. (1989) · British Journal of Cancer · doi:10.1038/bjc.1989.320 · Cited by 297
Caro, J. J., Johannes, C. B., Hartz, S. C., Marrs, R., & Miettinen, O. S. (1993) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116754 · Cited by 288
Harris, R., Whittemore, A. S., & Itnyre, J. (1992) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116428 · Cited by 275
Serum Gonadotropins and Steroid Hormones and the Development of Ovarian Cancer
Helzlsouer, K. J. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03530240036037 · Cited by 264
Whittemore, A. S., Harris, R., & ltnyre, J. (1992) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116429 · Cited by 264
Determinants of Ovarian Cancer Risk. I. Reproductive Experiences and Family History 23
(1983) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/71.4.711 · Cited by 256
Use of Menopausal Estrogens and Medroxyprogesterone in the United States, 1982-1992
Wysowski, D. (1995) · Obstetrics & Gynecology · doi:10.1016/0029-7844(94)00339-f · Cited by 193
Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis
Garg, P. (1998) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(98)00139-2 · Cited by 182
(1986) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/76.6.1057 · Cited by 168
Tamoxifen in Platinum-Refractory Ovarian Cancer: A Gynecologic Oncology Group Ancillary Report
Markman, M., Iseminger, K. A., Hatch, K. D., Creasman, W. T., Barnes, W. A., & DuBeshter, B. (1996) · Gynecologic Oncology · doi:10.1006/gyno.1996.0181 · Cited by 151
Noncontraceptive estrogens and progestins: use patterns over time.
Dl, K., Baum, C., & Forbes, M. B. (1985) · PubMed · Cited by 142
Reproductive variables, tobacco, ethanol, coffee and somatometry as risk factors for ovarian cancer
Polychronopoulou, A., Τζώνου, Α., Hsieh, C., Trichopoulos, D., KAPRINIS, G. S., Rebelakos, A., & Toupadaki, N. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910550312 · Cited by 140
Hormone replacement therapy and risk of epithelial ovarian cancer
Purdie, D. M., Bain, C., Siskind, V., Russell, P. J., Hacker, N. F., Ward, B. G., Quinn, M. A., & Green, A. C. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690731 · Cited by 112
Noncontraceptive Estrogen Use and the Occurrence of Ovarian Cancer 1 2
Vecchia, C. L., Liberati, A., & Franceschi, S. (1982) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/69.6.1207 · Cited by 109
Hartge, P. A., Hoover, R. N., McGowan, L., Lesher, L. P., & Norris, H. J. (1988) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a114902 · Cited by 105
Harlow, B. L., Weiss, N. S., Roth, G. J., Chu, J. Y., & Daling, J. R. (1988) · PubMed · Cited by 98
STILBŒSTROL (DIETHYLSTILBESTROL) AND THE RISK OF OVARIAN CANCER
Hoover, R. N., Gray, L., & Fraumeni, J. (1977) · The Lancet · doi:10.1016/s0140-6736(77)90667-5 · Cited by 91
Hempling, R. E., WONG, C., STEVENPIVER, M., NATARAJAN, N., & Mettlin, C. J. (1997) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(97)00118-x · Cited by 80
Hormonal therapy for menopause and ovarian cancer in a collaborative re-analysis of European studies
Negri, E., Τζώνου, Α., Beral, V., Λάγιου, Π., Trichopoulos, D., Parazzini, F., Franceschi, S., Booth, M., & Vecchia, C. L. (1999) · International Journal of Cancer · Cited by 79
Relative risks and benefits of long‐term estrogen replacement therapy: A decision analysis
Gorsky, R. D., Koplan, J. P., Peterson, H. B., & Thacker, S. B. (1994) · International Journal of Gynecology & Obstetrics · doi:10.1016/0020-7292(94)90483-9 · Cited by 74
Transcriptional activation of c-myc proto-oncogene by estrogen in human ovarian cancer cells
Chien, C.-H., Fung-Fang, W., & Hamilton, T. C. (1994) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(94)90140-6 · Cited by 59
Ey, W. M. (2000) · doi:10.1002/9780470757093.ch11 · Cited by 52
(1987) · Lung Cancer · doi:10.1016/s0169-5002(87)80393-8 · Cited by 45
Hormone-Replacement Therapy — Breast versus Heart versus Bone
Davidson, N. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506153322409 · Cited by 36
Paracetamol and risk of ovarian cancer mortality in a prospective study of women in the USA
Rodríguez, C., Henley, S. J., Calle, E. E., & Thun, M. J. (1998) · The Lancet · doi:10.1016/s0140-6736(05)60745-3 · Cited by 35
SERUM FSH, LH AND OESTRONE LEVELS IN POSTMENOPAUSAL PATIENTS ON OESTROGEN THERAPY
Larsson‐Cohn, U., Johansson, E. D. B., Kågedal, B., & Wallentin, L. C. (1978) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.1978.tb14896.x · Cited by 24
Cited by
Epidemiology of ovarian cancer: a review
Brett M., R., Brett M., R., Jennifer B., P., Thomas A., S., Jennifer B., P., & Thomas A., S. (2017) · Cancer Biology & Medicine · doi:10.20892/j.issn.2095-3941.2016.0084 · Cited by 1,524
Ovarian cancer and hormone replacement therapy in the Million Women Study
Beral, V. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60534-0 · Cited by 937
The 2012 Hormone Therapy Position Statement of The North American Menopause Society
(2012) · Menopause · doi:10.1097/gme.0b013e31824b970a · Cited by 785
Role of depression, stress, and trauma in HIV disease progression
Leserman, J. (2008) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3181777a5f · Cited by 662
Menopausal Hormone Replacement Therapy and Risk of Ovarian Cancer
Lacey, Jr. (2002) · JAMA · doi:10.1001/jama.288.3.334 · Cited by 606
Metadata
- Authors
- Rodriguez, C.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2001-03-21
- Volume
- 285
- Issue
- 11
- Pages
- 1460
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2140782377
- Cited by
- 424
- References
- 35
- FWCI
- 31.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.